Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal

PharmacoEconomics

Volumn 33, Issue 2, 2015, Pages 137-148

  Greenhalgh, Janette ^a   Bagust, Adrian ^a   Boland, Angela ^a   Oyee, James ^a   Trevor, Nicola ^b   Beale, Sophie ^a   Dundar, Yenal ^a   Hockenhull, Juliet ^a   Proudlove, Chris ^c   O’Reilly, Susan ^d  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b BMJ Technology Assessment Group ^*  (United Kingdom)

^c North West Medicines Information Centre ^*  (United Kingdom)

^d CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; ERIBULIN; ANTINEOPLASTIC AGENT; FURAN DERIVATIVE; KETONE;

ADVANCED CANCER; AUSTRALIA; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FEBRILE NEUTROPENIA; HEALTH CARE COST; HEALTH STATUS; HUMAN; INTENTION TO TREAT ANALYSIS; MULTICENTER STUDY (TOPIC); NEUTROPENIA; NORTH AMERICA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WESTERN EUROPE; BREAST NEOPLASMS; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; ECONOMICS; FEMALE; METASTASIS; PATHOLOGY; QUALITY ADJUSTED LIFE YEAR; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; FURANS; HUMANS; KETONES; NEOPLASM METASTASIS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 84921791127     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0214-2     Document Type: Review

References (20)

1. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. 2013. http://publications.nice.org.uk/guide-to-the-methods-of-technology-appraisal-2013-pmg9/the-appraisal-of-the-evidence-and-structured-decision-making.
2. National Institute for Health and Clinical Excellence. Breast cancer (advanced) eribulin: appraisal consultation document. 2011. Cited 2011 September 2011. http://www.nice.org.uk/guidance/TA250.
3. The International Agency for Research on Cancer. Latest world cancer statistics. 2013. www.iarc.fr/en/media-centre/pr/2013/pdfs/pr223_E.pdf.
4. Cancer Research UK. Breast cancer incidence statistics. 2014. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/incidence/.
5. Cancer Research UK (CancerHelp UK). Number of stages of breast cancer. 2011 March 2011. http://www.cancerhelp.org.uk/type/breast-cancer/treatment/number-stages-of-breast-cancer.
6. Berkowitz N, Gupta S, Silberman G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health. 2000;3(1):23–30.
7. Liverpool Reviews and Implementation Group (LRiG). Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor positive breast cancer which over-expresses HER2. 2010.
8. National Institute for Health and Clinical Excellence. Advanced breast cancer: NICE Clinical Guideline 81;2009.
9. Jassem J, Carroll C, Ward SE, Simpson E, Hind D. The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review. Eur J Cancer. 2009;45(16):2749–58.
10. European Medicines Agency. Halaven (eribulin). 2011.
11. European Medicines Agency. Assessment report for Halaven eribulin. London, 2011.
12. National Institute for Health and Clinical Excellence. Eribulin for the treatment of locally advanced and metastatic breast cancer: final scope. 2011. Cited 2011 February. http://www.nice.org.uk/guidance/TA250.
13. Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914–23.
14. Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roche H, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2010;28(25):3922–8.
15. Iwata H, Aogi K, Masuda N, Mukai H, Yoshida M, Rai Y, et al. Efficacy and safety of eribulin in Japanese patients with advanced breast cancer. J Clin Oncol Conf. 2010;28(15 SUPPL. 1).
16. Sacco JJ, MacBeth F, Bagust A, Clark P. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study PLoS ONE. 2010;5(1).
17. Department of Health. NHS reference costs (2008–2009). 2010.
18. Department of Health. NHS reference costs (2009–2010). 2011.
19. Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. British J Cancer. 2006;95:683–90.
20. National Institute for Health and Clinical Excellence. Supplementary advice to the Appraisal Committees—end of life treatments. 2009. http://www.nice.org.uk/aboutnice/howwework/devnicetech/endoflifetreatments.jsp?domedia=1&mid=88ACDAE5-19B9-E0B5-D422589714A8EC6D.